MedTrace Logo

Abbott Ventricular Tachycardia PAS

NCT05839873 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2025-10-17

No results posted yet for this study

Summary

This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study.

Conditions

  • Ventricular Tachycardia

Interventions

DEVICE

FlexAbility SE Ablation Catheter

Subjects receive ablation treatment.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Kristin Ruffner, PhD · Clinical Program Director

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2026-08-31
Completion
2026-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05839873 on ClinicalTrials.gov